148 related articles for article (PubMed ID: 29716606)
21. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
22. Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholders' capacity, needs, policy areas of demand and perspectives in Nigeria.
Uzochukwu BSC; Okeke C; O'Brien N; Ruiz F; Sombie I; Hollingworth S
Global Health; 2020 Jul; 16(1):58. PubMed ID: 32641066
[TBL] [Abstract][Full Text] [Related]
23. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
[TBL] [Abstract][Full Text] [Related]
24. The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies.
Haji Ali Afzali H; Street J; Merlin T; Karnon J
Int J Technol Assess Health Care; 2021 Jan; 37():e22. PubMed ID: 33455592
[TBL] [Abstract][Full Text] [Related]
25. The political economy of the assessment of value of new health technologies.
Karnon J; Edney L; Afzali H
J Health Serv Res Policy; 2018 Apr; 23(2):116-122. PubMed ID: 29320891
[TBL] [Abstract][Full Text] [Related]
26. Assessment of diagnostic tests to inform policy decisions--visual electrodiagnosis.
Johnston RV; Burrows E; Raulli A
Int J Technol Assess Health Care; 2003; 19(2):373-83. PubMed ID: 12862194
[TBL] [Abstract][Full Text] [Related]
27. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
[TBL] [Abstract][Full Text] [Related]
28. Issues facing the Australian Health Technology Assessment Review of medical technology funding.
O'Malley SP
Med J Aust; 2010 Jul; 193(1):30-3. PubMed ID: 20618111
[TBL] [Abstract][Full Text] [Related]
29. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Claxton K; Martin S; Soares M; Rice N; Spackman E; Hinde S; Devlin N; Smith PC; Sculpher M
Health Technol Assess; 2015 Feb; 19(14):1-503, v-vi. PubMed ID: 25692211
[TBL] [Abstract][Full Text] [Related]
30. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the impact of patient input in health technology assessments at NICE.
Livingstone H; Verdiel V; Crosbie H; Upadhyaya S; Harris K; Thomas L
Int J Technol Assess Health Care; 2021 Jan; 37():e33. PubMed ID: 33509314
[TBL] [Abstract][Full Text] [Related]
32. IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT WORK IN A HOSPITAL IN KAZAKHSTAN.
Kosherbayeva L; Hailey D; Kurakbaev K; Tsoy A; Zhuzzhanov O; Donbay A; Kumar A; Nadyrov K
Int J Technol Assess Health Care; 2016 Jan; 32(1-2):78-80. PubMed ID: 26956362
[TBL] [Abstract][Full Text] [Related]
33. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
34. Recommendations in health technology assessments worldwide.
Draborg E; Andersen CK
Int J Technol Assess Health Care; 2006; 22(2):155-60. PubMed ID: 16571190
[TBL] [Abstract][Full Text] [Related]
35. Impact assessment of Iran's health technology assessment programme.
Yazdizadeh B; Mohtasham F; Velayati A
Health Res Policy Syst; 2018 Feb; 16(1):15. PubMed ID: 29471838
[TBL] [Abstract][Full Text] [Related]
36. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
37. The development of funding recommendations for health technologies at the state level: A South Australian case study.
Lambert R; Carter D; Burgess N; Haji Ali Afzali H
Int J Health Plann Manage; 2018 Oct; 33(4):806-822. PubMed ID: 29676055
[TBL] [Abstract][Full Text] [Related]
38. Health technology assessment: research trends and future priorities in Europe.
Nielsen CP; Funch TM; Kristensen FB
J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
[TBL] [Abstract][Full Text] [Related]
39. Key principles for the improved conduct of health technology assessments for resource allocation decisions.
Drummond MF; Schwartz JS; Jönsson B; Luce BR; Neumann PJ; Siebert U; Sullivan SD
Int J Technol Assess Health Care; 2008; 24(3):244-58; discussion 362-8. PubMed ID: 18601792
[TBL] [Abstract][Full Text] [Related]
40. A systematic review of health technology assessment tools in sub-Saharan Africa: methodological issues and implications.
Kriza C; Hanass-Hancock J; Odame EA; Deghaye N; Aman R; Wahlster P; Marin M; Gebe N; Akhwale W; Wachsmuth I; Kolominsky-Rabas PL
Health Res Policy Syst; 2014 Dec; 12():66. PubMed ID: 25466570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
